Almost 1 in 2 patients with acute coronary syndrome are extremely high-risk and potential candidates for in-hospital triple lipid-lowering therapy: data from the CALLINICUS-Hellas Registry

Back

ESC Professional Premium Access

Almost 1 in 2 patients with acute coronary syndrome are extremely high-risk and potential candidates for in-hospital triple lipid-lowering therapy: data from the CALLINICUS-Hellas Registry

Session: Pharmacotherapy of acute coronary syndromes in clinical practice

Topic: Pharmacotherapy

Speaker: Professor L. Rallidis (Athens, GR)

Event: ESC Congress 2023

Congress Presentation

About the speaker

Professor Loukianos Rallidis

Attikon University Hospital, Athens (Greece)

0 follower

6 more presentations in this session

Beta-blockers after STEMI: prognostic impact and predictors of adherence, results from the real-world FAST-STEMI registry

Speaker: Doctor E. Ravetti (Turin, IT)

Changes of hospital-level variation in use of optimal medical treatment for long-term follow-up from a multi-level methodological approach

Speaker: Doctor H. Kwak (Daegu, KR)

Access

Abstract

Slides

Clinical impact of high platelet reactivity in patients with atrial fibrillation and concomitant percutaneous coronary intervention on dual or triple antithrombotic therapy

Speaker: Professor R. Marcucci (Florence, IT)

One-month dual antiplatelet therapy following stent implantation in patients with acute coronary syndromes and high bleeding risk

Speaker: Doctor C. Pivato (Milan, IT)

Ticagrelor versus Clopidogrel in diabetes patients afflicted with acute coronary syndrome stratified by renal function

Speaker: Doctor T. Wang (Taipei, TW)

Access the full session

Pharmacotherapy of acute coronary syndromes in clinical practice

Speakers: Professor L. Rallidis, Doctor E. Ravetti, Doctor H. Kwak, Professor R. Marcucci, Doctor C. Pivato...

Access

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

Almost 1 in 2 patients with acute coronary syndrome are extremely high-risk and potential candidates for in-hospital triple lipid-lowering therapy: data from the CALLINICUS-Hellas Registry

About the speaker

Professor Loukianos Rallidis

6 more presentations in this session

Beta-blockers after STEMI: prognostic impact and predictors of adherence, results from the real-world FAST-STEMI registry

Changes of hospital-level variation in use of optimal medical treatment for long-term follow-up from a multi-level methodological approach

Clinical impact of high platelet reactivity in patients with atrial fibrillation and concomitant percutaneous coronary intervention on dual or triple antithrombotic therapy

One-month dual antiplatelet therapy following stent implantation in patients with acute coronary syndromes and high bleeding risk

Ticagrelor versus Clopidogrel in diabetes patients afflicted with acute coronary syndrome stratified by renal function

Access the full session

Pharmacotherapy of acute coronary syndromes in clinical practice

About the event

ESC Congress 2023

ESC 365 is supported by